Emerging Trends in Cancer Biomarkers: From Molecular Signatures to Clinical Applications

Document Type : Review paper


Department of Biology, Shahrekord Branch, Islamic Azad University, Shahrekord, Iran


Background and aim: Cancer remains a global health challenge, necessitating the continual evolution of diagnostic and therapeutic strategies. This review paper explores the current landscape of cancer biomarkers, focusing on the transition from molecular signatures to their clinical applications. The aim is to provide a comprehensive overview of recent developments in cancer biomarker research and their potential impact on early detection, prognosis, and personalized treatment approaches.
Methods: We conducted an extensive literature review to identify relevant studies and developments in cancer biomarkers. The selected articles encompassed various types of biomarkers, including genetic, epigenetic, proteomic, and liquid biopsy markers. Our analysis considers the methodologies employed for biomarker discovery, validation, and clinical implementation. We also highlight the emerging technologies and bioinformatics tools that have revolutionized the field.
Results: Our review reveals a multitude of promising cancer biomarkers, many of which have transitioned from the laboratory to clinical settings. Advances in genomics and high-throughput sequencing technologies have enabled the identification of novel genetic mutations associated with cancer. Epigenetic modifications have provided valuable insights into cancer development and progression. Proteomic approaches have unveiled protein biomarkers with diagnostic and prognostic potential. Liquid biopsies, featuring circulating tumor DNA and exosomes, hold promise for real-time monitoring and treatment response assessment.
Conclusion: The emergence of cancer biomarkers in clinical oncology represents a significant paradigm shift. These molecular signatures offer improved diagnostic accuracy, early detection capabilities, and personalized treatment options. However, challenges remain, including standardization of methodologies, validation across diverse patient populations, and integration into routine clinical practice.


Main Subjects

Volume 2, Issue 2
Special Issue: Abstract and Papers from ICBMS23 (Turkey), ICBM23 (Hungary), ICCMM23 (Italy)
Pages 253-260
  • Receive Date: 19 December 2023
  • Accept Date: 19 December 2023